Published in Blood on September 25, 2003
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res (2005) 2.22
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood (2010) 2.17
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res (2007) 2.00
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med (2004) 1.84
Current issues in chronic graft-versus-host disease. Blood (2014) 1.83
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet (2009) 1.40
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood (2012) 1.31
Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood (2011) 1.30
Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood (2012) 1.22
New approaches for preventing and treating chronic graft-versus-host disease. Blood (2005) 1.20
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood (2012) 1.15
Advances in predicting acute GVHD. Br J Haematol (2012) 1.07
H-Y antibody development associates with acute rejection in female patients with male kidney transplants. Transplantation (2008) 1.07
Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med (2012) 1.02
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood (2008) 1.01
B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant (2014) 0.99
Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol (2010) 0.96
Clinical impact of H-Y alloimmunity. Immunol Res (2014) 0.96
Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am (2010) 0.94
H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. Proc Natl Acad Sci U S A (2013) 0.93
Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. Blood (2010) 0.93
Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood (2014) 0.93
Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation (2011) 0.91
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res (2010) 0.91
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2014) 0.86
Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood (2016) 0.84
Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia (2010) 0.84
Donor-recipient gender difference affects severity of dry eye after hematopoietic stem cell transplantation. Eye (Lond) (2011) 0.82
H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births. Hum Reprod (2010) 0.82
B-cell-directed therapy for chronic graft-versus-host disease. Haematologica (2010) 0.81
B cells and transplantation: an educational resource. Biol Blood Marrow Transplant (2009) 0.80
Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. BMC Immunol (2007) 0.79
Are there effective new strategies for the treatment of acute and chronic GvHD? Best Pract Res Clin Haematol (2008) 0.79
Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation. Transplantation (2015) 0.78
Chronic graft-versus-host disease: biological insights from pre-clinical and clinical studies. Blood (2016) 0.78
Biomarkers in chronic graft-versus-host disease. Expert Rev Hematol (2011) 0.77
Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol (2013) 0.77
Excess female siblings and male fetal loss in families with systemic lupus erythematosus. J Rheumatol (2013) 0.76
AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses. Bone Marrow Transplant (2016) 0.75
A case of membranous nephropathy as a manifestation of graft-versus-host disease. Kidney Res Clin Pract (2012) 0.75
Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease. Lung (2017) 0.75
In vitro cell-mediated immune responses to the male specific(H-Y) antigen in mice. J Exp Med (1975) 5.53
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Functional coherence of the human Y chromosome. Science (1997) 4.15
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood (2001) 3.32
Skin. Transplant Bull (1955) 3.02
Y-antigen killing by T cells of women is restricted by HLA. Nature (1977) 2.73
Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science (1995) 2.55
CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A (1999) 1.93
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med (2001) 1.88
Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science (1995) 1.87
Identification of a mouse male-specific transplantation antigen, H-Y. Nature (1995) 1.82
The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity (1997) 1.78
Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev (1997) 1.74
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med (2003) 1.61
Serological demonstration of H-Y (male) antigen on mouse sperm. Nature (1971) 1.58
The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med (2001) 1.53
The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol (2000) 1.49
Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature (1990) 1.45
The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood (2002) 1.41
Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol (1999) 1.38
The immunogenomics of minor histocompatibility antigens. Immunol Rev (2002) 1.32
Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens. Immunity (2000) 1.29
DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood (2000) 1.26
Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res (2002) 1.22
Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet (1990) 1.19
Minor histocompatibility antigens. Blood (1990) 1.18
Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol (1990) 1.17
Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood (2003) 1.10
Minor H antigens: genes and peptides. Transpl Immunol (2002) 1.09
Minor histocompatibility antigens. Curr Opin Immunol (1997) 1.08
Detection of H-Y (male) antigen on mouse lymph node cells by the cell to cell cytotoxicity test. Transplantation (1973) 1.03
Major histocompatibility complex-restricted antibody reactivity mainly, but not exclusively, directed against cells from male donors. J Exp Med (1979) 0.99
Major histocompatibility complex-restricted H-Y-specific antibodies and cytotoxic T lymphocytes may recognize different self determinants. J Exp Med (1982) 0.89
[Evidence of different leukocytic groups in man]. Schweiz Med Wochenschr (1954) 0.80
Targeting alloreactive T cells to hematopoietic system specific minor histocompatibility antigens for cellular immunotherapy of hematological malignancies after stem cell transplantation. Ann Hematol (2002) 0.79
Production of H-Y antibody by female mice that fail to reject male skin. Nat New Biol (1972) 0.79
Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood (2003) 20.10
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 4.46
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA (2013) 4.33
Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med (2011) 3.83
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell (2013) 3.49
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med (2013) 3.39
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 3.19
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 2.65
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood (2007) 2.54
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood (2006) 2.53
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg (2011) 2.43
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood (2011) 2.41
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2002) 2.40
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol (2011) 2.31
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood (2004) 2.30
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood (2011) 2.25
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood (2010) 2.17
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2011) 2.11
Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood (2011) 2.03
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant (2011) 2.02
Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res (2005) 2.02
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest (2010) 2.00
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res (2007) 2.00
A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood (2012) 2.00